Does the media refer more to AVTX or RCUS?

In the previous week, Arcus Biosciences had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Arcus Biosciences and 3 mentions for Avalo Therapeutics. Arcus Biosciences' average media sentiment score of 0.30 beat Avalo Therapeutics' score of 0.11 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is DYN or AVTX more profitable?

Avalo Therapeutics' return on equity of -58.03% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% Avalo Therapeutics N/A -58.03% -48.22%

Does the media favor DYN or AVTX?

In the previous week, Dyne Therapeutics had 13 more articles in the media than Avalo Therapeutics. MarketBeat recorded 16 mentions for Dyne Therapeutics and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Dyne Therapeutics' score of 0.01 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ZLAB or AVTX?

In the previous week, Zai Lab had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Zai Lab's score of -0.44 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AVTX or NAMS?

In the previous week, NewAmsterdam Pharma had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 3 mentions for Avalo Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.23 beat Avalo Therapeutics' score of 0.11 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 2 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer GMTX or AVTX?

Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 200.87%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Avalo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85

Is GMTX or AVTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Avalo Therapeutics N/A -58.03% -48.22%

Avalo Therapeutics (AVTX) Competitors

$14.60 -0.39 (-2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$14.60 0.00 (0.00%)

As of 07:30 PM Eastern

Compare

AVTX vs. RCUS, DYN, ZLAB, NAMS, and GMTX

Should you buy Avalo Therapeutics stock or one of its competitors? Avalo Therapeutics's main competitors and comparable companies include Arcus Biosciences (RCUS), Dyne Therapeutics (DYN), Zai Lab (ZLAB), NewAmsterdam Pharma (NAMS), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avalo Therapeutics compare to Arcus Biosciences?

Avalo Therapeutics (NASDAQ:AVTX) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Avalo Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Arcus Biosciences had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 5 mentions for Arcus Biosciences and 3 mentions for Avalo Therapeutics. Arcus Biosciences' average media sentiment score of 0.30 beat Avalo Therapeutics' score of 0.11 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Avalo Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Avalo Therapeutics' return on equity of -58.03% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Avalo Therapeutics presently has a consensus target price of $45.10, indicating a potential upside of 200.87%. Arcus Biosciences has a consensus target price of $38.30, indicating a potential upside of 56.80%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Avalo Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A
Arcus Biosciences	$247M	12.59	-$353M	-$3.90	N/A

Summary

Avalo Therapeutics and Arcus Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Avalo Therapeutics (NASDAQ:AVTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Dyne Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Avalo Therapeutics' return on equity of -58.03% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Dyne Therapeutics presently has a consensus price target of $33.07, suggesting a potential upside of 117.58%. Avalo Therapeutics has a consensus price target of $45.10, suggesting a potential upside of 200.87%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Avalo Therapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Avalo Therapeutics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Dyne Therapeutics had 13 more articles in the media than Avalo Therapeutics. MarketBeat recorded 16 mentions for Dyne Therapeutics and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Dyne Therapeutics' score of 0.01 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Avalo Therapeutics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Avalo Therapeutics (NASDAQ:AVTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, Zai Lab had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Zai Lab and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Zai Lab's score of -0.44 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalo Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.02	-$175.54M	-$1.71	N/A
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A

Zai Lab has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Zai Lab presently has a consensus target price of $37.25, suggesting a potential upside of 53.10%. Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 200.87%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Avalo Therapeutics beats Zai Lab on 9 of the 17 factors compared between the two stocks.

How does Avalo Therapeutics compare to NewAmsterdam Pharma?

Avalo Therapeutics (NASDAQ:AVTX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Avalo Therapeutics has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A
NewAmsterdam Pharma	$22.50M	123.26	-$203.82M	-$2.16	N/A

In the previous week, NewAmsterdam Pharma had 9 more articles in the media than Avalo Therapeutics. MarketBeat recorded 12 mentions for NewAmsterdam Pharma and 3 mentions for Avalo Therapeutics. NewAmsterdam Pharma's average media sentiment score of 0.23 beat Avalo Therapeutics' score of 0.11 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Avalo Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Avalo Therapeutics presently has a consensus price target of $45.10, suggesting a potential upside of 200.87%. NewAmsterdam Pharma has a consensus price target of $49.73, suggesting a potential upside of 114.34%. Given Avalo Therapeutics' higher probable upside, research analysts plainly believe Avalo Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Avalo Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Avalo Therapeutics (NASDAQ:AVTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Gemini Therapeutics' return on equity of -38.78% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Avalo Therapeutics	N/A	-58.03%	-48.22%

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Gemini Therapeutics has higher earnings, but lower revenue than Avalo Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A

In the previous week, Avalo Therapeutics had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Avalo Therapeutics and 0 mentions for Gemini Therapeutics. Avalo Therapeutics' average media sentiment score of 0.11 beat Gemini Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Avalo Therapeutics	Neutral

Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 200.87%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Avalo Therapeutics beats Gemini Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTX vs. The Competition

Export

Metric	Avalo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$783.00M	$3.88B	$7.17B	$13.38B
Dividend Yield	N/A	3.65%	2.53%	17.32%
P/E Ratio	-3.34	13.06	274.64	26.20
Price / Sales	13,049.97	1,310.05	608.57	90.53
Price / Cash	N/A	39.04	27.22	34.70
Price / Book	3.25	17.13	11.26	6.40
Net Income	-$78.26M	-$23.20M	$3.49B	$381.07M
7 Day Performance	-3.18%	-2.60%	-1.68%	-0.66%
1 Month Performance	-24.08%	-10.22%	-5.97%	-4.51%
1 Year Performance	8.96%	19.55%	8.11%	1.82%

Avalo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTX Avalo Therapeutics	2.2506 of 5 stars	$14.60 -2.6%	$45.10 +208.9%	+11.9%	$783.00M	$60K	N/A	33
RCUS Arcus Biosciences	2.8445 of 5 stars	$25.67 +2.7%	$38.30 +49.2%	+83.0%	$3.18B	$117M	N/A	601	Analyst Upgrade
DYN Dyne Therapeutics	3.3454 of 5 stars	$16.21 -0.8%	$33.31 +105.5%	+16.4%	$3.05B	N/A	N/A	258	Analyst Revision
ZLAB Zai Lab	1.7916 of 5 stars	$25.93 +0.9%	$37.25 +43.7%	-27.9%	$2.92B	$460.16M	N/A	1,784
NAMS NewAmsterdam Pharma	3.6137 of 5 stars	$23.81 +1.0%	$49.73 +108.9%	-24.4%	$2.82B	$22.50M	N/A	100	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTX) was last updated on 10/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalo Therapeutics (AVTX) Competitors

AVTX vs. RCUS, DYN, ZLAB, NAMS, and GMTX

How does Avalo Therapeutics compare to Arcus Biosciences?

Summary

How does Avalo Therapeutics compare to Dyne Therapeutics?

Summary

How does Avalo Therapeutics compare to Zai Lab?

Summary

How does Avalo Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Avalo Therapeutics compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalo Therapeutics (AVTX) Competitors

AVTX vs. RCUS, DYN, ZLAB, NAMS, and GMTX

How does Avalo Therapeutics compare to Arcus Biosciences?

Which has more risk and volatility, AVTX or RCUS?

Do institutionals & insiders have more ownership in AVTX or RCUS?

Does the media refer more to AVTX or RCUS?

Is AVTX or RCUS more profitable?

Do analysts rate AVTX or RCUS?

Which has stronger earnings and valuation, AVTX or RCUS?

Summary

How does Avalo Therapeutics compare to Dyne Therapeutics?

Which has more risk and volatility, DYN or AVTX?

Is DYN or AVTX more profitable?

Do analysts rate DYN or AVTX?

Which has better earnings and valuation, DYN or AVTX?

Do institutionals & insiders hold more shares of DYN or AVTX?

Does the media favor DYN or AVTX?

Summary

How does Avalo Therapeutics compare to Zai Lab?

Does the media favor ZLAB or AVTX?

Which has stronger earnings and valuation, ZLAB or AVTX?

Which has more volatility & risk, ZLAB or AVTX?

Is ZLAB or AVTX more profitable?

Do analysts prefer ZLAB or AVTX?

Do insiders and institutionals hold more shares of ZLAB or AVTX?

Summary

How does Avalo Therapeutics compare to NewAmsterdam Pharma?

Which has higher earnings and valuation, AVTX or NAMS?

Does the media favor AVTX or NAMS?

Do insiders & institutionals have more ownership in AVTX or NAMS?

Is AVTX or NAMS more profitable?

Do analysts prefer AVTX or NAMS?

Which has more volatility and risk, AVTX or NAMS?

Summary

How does Avalo Therapeutics compare to Gemini Therapeutics?

Is GMTX or AVTX more profitable?

Do insiders and institutionals have more ownership in GMTX or AVTX?

Which has more volatility & risk, GMTX or AVTX?

Which has better valuation and earnings, GMTX or AVTX?

Does the media prefer GMTX or AVTX?

Do analysts prefer GMTX or AVTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools